Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3511 - A randomized double-blind phase II trial evaluating maintenance PARP inhibitor Olaparib versus placebo in patients with platinum-sensitive advanced non-small cell lung cancer: PIPSeN trial

Date

09 Sep 2017

Session

Poster display session

Presenters

Sophie Postel-Vinay

Citation

Annals of Oncology (2017) 28 (suppl_5): v460-v496. 10.1093/annonc/mdx380

Authors

S. Postel-Vinay1, D. Planchard2, A.L. Ortega Granados3, A. Gazzah1, M.A. Sala Gonzalez4, M. Majem5, C.J. Camps6, A. Abou-Lauvergne7, J. Pignon8, J. Cadranel9, J. Bennouna10, F. Barlesi11, M.R. Garcia Campelo12, S. Viteri13, B. Besse14, J. Coves Sarto15, B. Massuti Sureda16, J. Soria2, R. Rosell17

Author affiliations

  • 1 Départemement D’innovation Thérapeutique Et Des Essais Précoces (ditep), Institut Gustave Roussy, 94800 - Villejuif/FR
  • 2 Medical Oncology Department, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 3 Oncología Médica, Complejo Hospitalario de Jaén, 23006 - Jaén/ES
  • 4 Medical Oncology Department, Hospital de Basurto, 48013 - Bilbao/ES
  • 5 Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, 8026 - Barcelona/ES
  • 6 Medical Oncology Department, Hospital General Universitario Valencia, 46018 - Valencia/ES
  • 7 Recherche Clinique, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 8 Département De Biostatistiques, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 9 Medical Oncology Department, APHP, CancerEst, Tenon University Hospital, 75020 - Paris/FR
  • 10 Oncology, CHU de Nantes, 44093 - Nantes/FR
  • 11 Multidisciplinary Oncology & Therapeutic Innovations, Aix Marseille University - Assistance Publique des Hôpitaux de Marseille, Marseille/FR
  • 12 Medical Oncology, Complejo Hospitalario Universitario de A Coruña, A Coruña/ES
  • 13 Oncology Department, Instituto Universitario USP Dexeus, 8028 - Barcelona/ES
  • 14 Cancer Medicine, Institut de Cancérologie Gustave Roussy, 94805 - Villejuif/FR
  • 15 Medical Oncology, Hospital Son Llatzer, 7198 - Palma de Mallorca/ES
  • 16 Medical Oncology, Hospital General Universitario de Alicante, 3010 - Alicante/ES
  • 17 Medical Oncology Department, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, 8916 - Badalona/ES
More

Resources

Abstract 3511

Background

Poly (ADP-ribose) polymerase inhibitors (PARPi) have demonstrated impressive efficacy in BRCA-mutated gynaecological malignancies. Several lines of evidence now support that the DNA repair (DDR)-deficient populations that benefit from PARPi go far beyond BRCA-deficiency. Non-small cell lung cancer (NSCLC), the first cause of cancer death worldwide, displays frequent DDR defects, the most frequent being ERCC1. This defect leads to platinum and PARPi sensitivity. Beyond ERCC1, DDR defects leading to platinum sensitivity widely overlap with those underlying PARPi sensitivity. Maintenance PARPi could therefore benefit to patients (pts) with platinum-sensitive NSCLC. Olaparib (Lynparza®, Astra Zeneca), a potent and selective PARPi, was the first-in-class approved PARPi in BRCA-mutated ovarian cancer.

Trial design

PIPSeN is a randomized double-blind phase II investigator-initiated study evaluating maintenance Olaparib versus placebo in pts with platinum-sensitive advanced NSCLC. Chemonaïve ECOG PS 0-1 pts with stage III-IV NSCLC with no EGFR mutation or ALK translocation are eligible. Treatment consists of an “induction phase” of 4-6 cycles platinum-based therapy (any doublet), followed by a “randomized phase” where pts presenting with partial or complete response are randomized between Olaparib maintenance (tablets; 300mg bd) and placebo until progression or unacceptable toxicity. Primary objective is to assess the efficacy of maintenance Olaparib as measured by Progression-Free Survival from randomisation (RECIST v1.1). Secondary objectives include comparison of overall survival, disease control rate and safety. Randomization is stratified according to age, histology and country. With an anticipated HR = 0.65 (bilateral α = 0.2; β = 0.2), approximately 500 enrolled pts will be required to randomize 144 pts and observe 97 events. Recruitment is ongoing since the 5th of Feb. 2016 across 21 centres in France and Spain; 95 (19) pts have been enrolled (randomised) to date. Translational studies looking notably for biomarkers of platinum and PARPi sensitivity (using WES, RNAseq, proteomics and ctDNA) are associated.

Clinical trial identification

EudraCT: 2014-005586-75 NCT02679963

Legal entity responsible for the study

Gustave Roussy Cancer Campus (sponsor), in collaboration with the Spanish Lung Cancer Group

Funding

Astra Zeneca

Disclosure

D. Planchard: Consultancy fees for AstraZeneca, Boehringer Ingelheim, BMS, Lilly, MSD, Pfizer, Roche, Novartis, Chugai. M. Majem: Merck Sharp and Dhome, Boerhinger Ingelheim, Bristol-Myers Squibb, Roche, Novartis honoraria. F. Barlesi: AstraZeneca Honoraria. S. Viteri: Consulting/advisory (BI, Clovis, Idea Pharma, Novartis, Roche, Targovax), Research (AbbVie, ARIAD, Astex, AstraZeneca/MedImmune, BI, Clovis, CytRx, Daiichi Sankyo, GSK, Hanmi, Incyte, Merck, Novartis, Pfizer, Puma, Roche, Servier, Vaxon) B. Besse: Research grants from Astra Zeneca. J-C. Soria: Consultancy fees from AZ. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.